What Kazia Therapeutics Ltd does.

The ongoing principal business of the Company has been pharmaceutical drug development. The Company is an emerging oncology-focused biotechnology company that has a portfolio of development candidates, diversified across several distinct technologies, with the potential to yield first-in-class and best-in-class agents in a range of oncology indications.

Kazia’s lead program is Paxalisib, (formerly known as GDC-0084), an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, that was specifically designed to treat brain cancer.

Paxalisib was developed by Genentech, Inc (South San Francisco, California) and the company entered into a worldwide exclusive license for the asset in October 2016. Prior to this transaction, Genentech had completed an extensive pre-clinical development program that provided convincing validation for Paxalisib as a potential drug for brain cancer. Genentech also completed a phase I clinical trial in 47 patients with advanced recurrent grade III and grade IV glioma (NCT01547546). The most common adverse events were oral mucositis and hyperglycemia. Per ANO criteria, 40% of patients exhibited a best observable response of stable disease, and 26% demonstrated a metabolic partial response on FDG-PET.

Revenue and profit, by fiscal year.

More on KZIA.

• Kazia Therapeutics Ltd summary
• Kazia Therapeutics Ltd financial statements
• Kazia Therapeutics Ltd key metrics
• Kazia Therapeutics Ltd health scores and style box
• Kazia Therapeutics Ltd earnings
• Kazia Therapeutics Ltd dividends
• Kazia Therapeutics Ltd valuation
• Kazia Therapeutics Ltd ownership and insiders
• Kazia Therapeutics Ltd peers

Figures from Kazia Therapeutics Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.